Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate

• Published in: Vox sanguinis Vol. 104; no. 1; pp. 1 - 6
• Main Authors: Burnouf, T., Chou, M.-L., Cheng, L.-H., Li, Z.-R., Wu, Y.-W., El-Ekiaby, M., Tsai, K.-H.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.01.2013; S. Karger AG
• Subjects: Animals; Blood Preservation; Blood products; Blood Safety; Blood Transfusion; Blood transfusions; Cercopithecus aethiops; Complement System Proteins; cryoprecipitate; Culicidae; Dengue; Dengue - prevention & control; Dengue fever; Dengue virus; Dengue Virus - drug effects; Detergents; Factor VIII - chemistry; Fibrinogen - chemistry; Humans; Octoxynol - pharmacology; Organophosphates - pharmacology; plasma; Plasma - drug effects; solvent/detergent; Solvents; Solvents - chemistry; Time Factors; Vero Cells; Virus Inactivation
• ISSN: 0042-9007; 1423-0410
• DOI: 10.1111/j.1423-0410.2012.01621.x

Background and Objectives  A minipool solvent/detergent (S/D; 1% TnBP/1% Triton X‐45; 31°C) process was developed for viral inactivation of plasma and cryoprecipitate used for transfusion. The goal of this study was to determine the rate and extent of inactivation of dengue virus (DENV) during this process. Materials and Methods  DENV‐1 was propagated using C6/36 mosquito cells to an infectivity titre close to 9 log and spiked (10% v/v) into individual plasma and cryoprecipitate samples from two distinct donors. Samples were taken right after spiking and during viral inactivation treatment by 1% TnBP‐1% Triton X‐45 at 31°C. DENV‐1 infectivity was assessed on Vero E6 cells by a focus‐forming assay (FFA). Culture medium and complement‐inactivated plasma were used as experimental controls. Experiments were done in duplicate. Results  DENV‐1 infectivity was 7·5 log in spiked plasma and 7·1 and 7·3 log in spiked cryoprecipitate. There was no loss of DENV‐1 infectivity in the spiked materials, nor in the controls not subjected to S/D treatment. No infectivity was found in plasma and cryoprecipitate subjected to S/D treatment at the first time‐point evaluated (10 min). Conclusion  DENV‐1 was strongly inactivated in plasma and cryoprecipitate, respectively, within 10 min of 1% TnBP/1% Triton X‐45 treatment at 31°C. These data provide a reassurance of the safety of such S/D‐treated plasma and cryoprecipitate with regard to the risk of transmission of all DENV serotypes and other flaviviruses.